Get started
MADRIGAL PHARMACEUTICALS INCMADRIGAL PHARMACEUTICALS INCMADRIGAL PHARMACEUTICALS INC

MADRIGAL PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast

1MDGL chart


Full chart

1MDGL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.33 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−16.7 EUR
Net income (FY)
‪−450.04 M‬ EUR
Revenue (FY)
‪174.00 M‬ EUR
Shares float
‪20.08 M‬
Beta (1Y)
0.45

Employees


Employees (FY)
528
Change (1Y)
+152 +40.43%
Revenue / Employee (1Y)
‪329.55 K‬ EUR
Net income / Employee (1Y)
‪−852.35 K‬ EUR

About Madrigal Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
William J. Sibold
Website
madrigalpharma.com
Headquarters
West Conshohocken
Founded
2000
FIGI
BBG01TNXBVD2
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1MDGL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Check out other big names from the same industry as 1MDGL.

Frequently Asked Questions


The current price of 1MDGL is 240.9 EUR — it has increased by 0.92% in the past 24 hours. Watch MADRIGAL PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange MADRIGAL PHARMACEUTICALS INC stocks are traded under the ticker 1MDGL.
1MDGL stock has fallen by −4.48% compared to the previous week, the month change is a −12.65% fall, over the last year MADRIGAL PHARMACEUTICALS INC has showed a −12.65% decrease.
We've gathered analysts' opinions on MADRIGAL PHARMACEUTICALS INC future price: according to them, 1MDGL price has a max estimate of 483.26 EUR and a min estimate of 221.94 EUR. Watch 1MDGL chart and read a more detailed MADRIGAL PHARMACEUTICALS INC stock forecast: see what analysts think of MADRIGAL PHARMACEUTICALS INC and suggest that you do with its stocks.
1MDGL reached its all-time high on Apr 30, 2025 with the price of 301.7 EUR, and its all-time low was 239.6 EUR and was reached on May 23, 2025. View more price dynamics on 1MDGL chart.
See other stocks reaching their highest and lowest prices.
1MDGL stock is 0.91% volatile and has beta coefficient of 0.45. Track MADRIGAL PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is MADRIGAL PHARMACEUTICALS INC there?
Today MADRIGAL PHARMACEUTICALS INC has the market capitalization of ‪5.33 B‬, it has decreased by −9.45% over the last week.
Yes, you can track MADRIGAL PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MADRIGAL PHARMACEUTICALS INC is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
1MDGL earnings for the last quarter are −3.07 EUR per share, whereas the estimation was −3.46 EUR resulting in a 11.43% surprise. The estimated earnings for the next quarter are −3.09 EUR per share. See more details about MADRIGAL PHARMACEUTICALS INC earnings.
MADRIGAL PHARMACEUTICALS INC revenue for the last quarter amounts to ‪126.87 M‬ EUR, despite the estimated figure of ‪105.98 M‬ EUR. In the next quarter, revenue is expected to reach ‪138.35 M‬ EUR.
1MDGL net income for the last quarter is ‪−67.70 M‬ EUR, while the quarter before that showed ‪−57.39 M‬ EUR of net income which accounts for −17.95% change. Track more MADRIGAL PHARMACEUTICALS INC financial stats to get the full picture.
No, 1MDGL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has 528 employees. See our rating of the largest employees — is MADRIGAL PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MADRIGAL PHARMACEUTICALS INC EBITDA is ‪−391.78 M‬ EUR, and current EBITDA margin is −275.78%. See more stats in MADRIGAL PHARMACEUTICALS INC financial statements.
Like other stocks, 1MDGL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MADRIGAL PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.